Zelos Therapeutics

Zelos Therapeutics specializes in the development of innovative treatments for bone disorders and related indications in large, underserved markets. Led by an experienced team of biopharmaceutical executives and funded by leading health care investors, Zelos is advancing a portfolio of product opportunities in Phase 2 and 3 with significant commercial potential into late stage clinical trials. The company is pursuing programs linked by the common mechanism of stimulating bone formation – specifically parathyroid hormone (PTH) analogs - to provide therapeutic benefit in key indications including osteoporosis, orthopedics and renal bone disease.